{"id":"lacidipine","rwe":[],"tags":[{"label":"lacidipine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 3A4","category":"target"},{"label":"CYP3A4","category":"gene"},{"label":"TBXAS1","category":"gene"},{"label":"CYP2C19","category":"gene"},{"label":"C08CA09","category":"atc"},{"label":"Active","category":"status"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":67.869,"date":"","count":11,"signal":"Procalcitonin abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=68)"},{"llr":54.518,"date":"","count":58,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 58 times (LLR=55)"},{"llr":53.289,"date":"","count":11,"signal":"Encephalomalacia","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=53)"},{"llr":50.012,"date":"","count":12,"signal":"PO2 decreased","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=50)"},{"llr":45.067,"date":"","count":11,"signal":"PCO2 decreased","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=45)"},{"llr":42.903,"date":"","count":26,"signal":"International normalised ratio increased","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=43)"},{"llr":40.494,"date":"","count":12,"signal":"Lymphocyte count increased","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=40)"},{"llr":37.294,"date":"","count":21,"signal":"Melaena","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=37)"},{"llr":36.825,"date":"","count":6,"signal":"Acquired macroglossia","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=37)"},{"llr":35.823,"date":"","count":11,"signal":"Device related sepsis","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=36)"},{"llr":34.46,"date":"","count":8,"signal":"Scrotal oedema","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=34)"},{"llr":29.823,"date":"","count":9,"signal":"Procedural haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=30)"},{"llr":29.435,"date":"","count":11,"signal":"Monocyte count increased","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=29)"}],"commonSideEffects":[{"effect":"Procalcitonin abnormal","drugRate":"LLR 68","severity":"common"},{"effect":"Drug interaction","drugRate":"LLR 55","severity":"common"},{"effect":"Encephalomalacia","drugRate":"LLR 53","severity":"common"},{"effect":"PO2 decreased","drugRate":"LLR 50","severity":"common"},{"effect":"PCO2 decreased","drugRate":"LLR 45","severity":"common"},{"effect":"International normalised ratio increased","drugRate":"LLR 43","severity":"common"},{"effect":"Lymphocyte count increased","drugRate":"LLR 40","severity":"common"},{"effect":"Melaena","drugRate":"LLR 37","severity":"common"},{"effect":"Acquired macroglossia","drugRate":"LLR 37","severity":"common"},{"effect":"Device related sepsis","drugRate":"LLR 36","severity":"common"},{"effect":"Scrotal oedema","drugRate":"LLR 34","severity":"common"},{"effect":"Procedural haemorrhage","drugRate":"LLR 30","severity":"common"},{"effect":"Monocyte count increased","drugRate":"LLR 29","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"motens","offLabel":[],"synonyms":["lacidipine","lacipil","lacirex","GR-43659X","motens"],"timeline":[],"aiSummary":"Lacidipine, also known as Moten, is a small molecule lacidipine drug that targets Cytochrome P450 3A4. It is a calcium channel blocker used to treat hypertension. The commercial status of lacidipine is unclear, and it is not FDA-approved. Lacidipine has a bioavailability of 18%. Further information on its half-life, generic manufacturers, and patent status is not available.","approvals":[],"brandName":"Motens","ecosystem":[],"mechanism":{"target":"Adenosine receptor A3, Cytochrome P450 2C19, Cytochrome P450 2C9","targets":[{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"},{"gene":"TBXAS1","source":"DrugCentral","target":"Thromboxane-A synthase","protein":"Thromboxane-A synthase"},{"gene":"CYP2C19","source":"DrugCentral","target":"Cytochrome P450 2C19","protein":"Cytochrome P450 2C19"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"},{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"CACNA1C","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1C"},{"gene":"CACNA1D","source":"DrugCentral","target":"Voltage-gated L-type calcium channel","protein":"Voltage-dependent L-type calcium channel subunit alpha-1D"}],"modality":"Small Molecule","drugClass":"lacidipine","explanation":"Imagine your blood vessels are like roads with traffic flowing through them. Calcium channels are like on-ramps that let more traffic in, making the road more congested. By blocking these on-ramps, lacidipine reduces the amount of calcium flowing into the blood vessels, which helps to relax the blood vessel walls and improve blood flow.","oneSentence":"Lacidipine works by blocking calcium channels in the blood vessels, which helps to lower blood pressure.","technicalDetail":"Lacidipine exerts its effects by selectively and competitively inhibiting the L-type calcium channels, which are responsible for the influx of calcium ions into vascular smooth muscle cells, thereby reducing vascular resistance and lowering blood pressure."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1532","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LACIDIPINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LACIDIPINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:13:33.668188","biosimilars":[],"competitors":[{"drugName":"amlodipine","drugSlug":"amlodipine","fdaApproval":"1992-07-31","patentExpiry":"Feb 24, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"felodipine","drugSlug":"felodipine","fdaApproval":"1991-07-25","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"isradipine","drugSlug":"isradipine","fdaApproval":"1990-12-20","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nicardipine","drugSlug":"nicardipine","fdaApproval":"1988-12-21","patentExpiry":"Dec 26, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nifedipine","drugSlug":"nifedipine","fdaApproval":"1981-12-31","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nimodipine","drugSlug":"nimodipine","fdaApproval":"1988-12-28","patentExpiry":"Apr 16, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nisoldipine","drugSlug":"nisoldipine","fdaApproval":"1995-02-02","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clevidipine","drugSlug":"clevidipine","fdaApproval":"2008-08-01","patentExpiry":"Oct 10, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"lacidipine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amlodipine","brandName":"amlodipine","genericName":"amlodipine","approvalYear":"1992","relationship":"same-class"},{"drugId":"felodipine","brandName":"felodipine","genericName":"felodipine","approvalYear":"1991","relationship":"same-class"},{"drugId":"isradipine","brandName":"isradipine","genericName":"isradipine","approvalYear":"1990","relationship":"same-class"},{"drugId":"nicardipine","brandName":"nicardipine","genericName":"nicardipine","approvalYear":"1988","relationship":"same-class"},{"drugId":"nifedipine","brandName":"nifedipine","genericName":"nifedipine","approvalYear":"1981","relationship":"same-class"},{"drugId":"nimodipine","brandName":"nimodipine","genericName":"nimodipine","approvalYear":"1988","relationship":"same-class"},{"drugId":"nisoldipine","brandName":"nisoldipine","genericName":"nisoldipine","approvalYear":"1995","relationship":"same-class"},{"drugId":"clevidipine","brandName":"clevidipine","genericName":"clevidipine","approvalYear":"2008","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT00338338","phase":"PHASE4","title":"The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-07","conditions":["Uncomplicated Hypertension","Hypertension","Essential"],"enrollment":70,"completionDate":"2007-09-14"},{"nctId":"NCT01587742","phase":"","title":"IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":["Hypertension"],"enrollment":1,"completionDate":"2014-08"},{"nctId":"NCT02264158","phase":"PHASE1","title":"Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-09","conditions":["Healthy"],"enrollment":149,"completionDate":""},{"nctId":"NCT02240641","phase":"","title":"Effect of Caldine® on Renal Function in Balanced Hypertension","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"1998-05","conditions":["Hypertension"],"enrollment":5417,"completionDate":""},{"nctId":"NCT02235402","phase":"PHASE4","title":"A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1997-12","conditions":["Hypertension"],"enrollment":26,"completionDate":""},{"nctId":"NCT02235415","phase":"","title":"Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-06","conditions":["Hypertension"],"enrollment":24526,"completionDate":""},{"nctId":"NCT02232607","phase":"PHASE2","title":"Efficacy and Safety of Lacidipine in Chronic Stable Angina","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":["Angina Pectoris"],"enrollment":283,"completionDate":""},{"nctId":"NCT02218684","phase":"PHASE1","title":"Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-09","conditions":["Healthy"],"enrollment":27,"completionDate":""},{"nctId":"NCT02209649","phase":"PHASE1","title":"Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-10","conditions":["Healthy"],"enrollment":12,"completionDate":""},{"nctId":"NCT02203500","phase":"PHASE1","title":"Tolerability and Pharmacokinetics of Lacidipine With and Without the Co-administration of Telmisartan in Female and Male Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-10","conditions":["Healthy"],"enrollment":26,"completionDate":""},{"nctId":"NCT02177331","phase":"PHASE3","title":"Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1995-06","conditions":["Hypertension"],"enrollment":53,"completionDate":""},{"nctId":"NCT00328965","phase":"PHASE4","title":"Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11","conditions":["Diabetes Mellitus, Type 2","Essential Hypertension"],"enrollment":0,"completionDate":"2006-05"},{"nctId":"NCT00460915","phase":"PHASE4","title":"Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean ISH Patients Aged 60 to 80 Years","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2007-01","conditions":["Hypertension"],"enrollment":204,"completionDate":"2010-02"},{"nctId":"NCT00533858","phase":"PHASE4","title":"Effect of Lacidipine and Losartan on 24 Hour Systolic Blood Pressure Variability in Elderly Hypertensive Patients","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2007-09","conditions":["Hypertension"],"enrollment":160,"completionDate":"2008-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000179165","NDDF":"004453","UNII":"260080034N","VUID":"4025250","CHEBI":"CHEBI:135737","VANDF":"4025250","INN_ID":"6093","RXNORM":"28382","UMLSCUI":"C0064568","ChEMBL_ID":"CHEMBL460291","KEGG_DRUG":"D04657","DRUGBANK_ID":"DB09236","PUBCHEM_CID":"5311217","SNOMEDCT_US":"319299000","IUPHAR_LIGAND_ID":"11740","MESH_SUPPLEMENTAL_RECORD_UI":"C060285"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"18%"},"publicationCount":469,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C08CA09","allCodes":["C08CA09"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}